N,N'-dibenzylethane-1,2-diaminium bis{6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate}

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: N,N'-dibenzylethane-1,2-diaminium bis{6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate}
• 英文别名: (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;benzyl-[2-(benzylazaniumyl)ethyl]azanium
• 化学式: C48H58N8O8S2
• 分子量: 939.2
• InChiKey: RHKWJSNGCNASTF-PHGYPNQBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  66
• 可旋转键数：
  15
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  300
• 氢给体数：
  8
• 氢受体数：
  14

文献信息

• Pharmaceutical compositions comprising an antibiotic and bromhexine, and process for their preparation
  申请人：New Pharma Research Sweden AB

  公开号：EP1121940A1

  公开（公告）日：2001-08-08

  Compositions for the prophylactic or therapeutic treatment of bacterial diseases in humans and animals, comprising as essential active ingredients a quinolone- or naphtyridone-type antibiotic or an active chemical derivative thereof and bromhexine-HCl, glacial acetic acid, water and a stabilizing agent. The compositions are stable upon storage over a broad range of temperature. The invention concerns also the combined use of a quinolone- or naphtyridone-type antibiotic or an active chemical derivative thereof and bromhexine-HCl for the treatment of bacterial infections in humans and animals, and a process for the preparation of the aforementioned compositions.

  用于预防或治疗人类和动物细菌性疾病的组合物，其基本活性成分包括喹诺酮或萘啶酮类抗生素或其活性化学衍生物以及溴己新-HCl、冰醋酸、水和稳定剂。这种组合物在广泛的温度范围内储存都很稳定。本发明还涉及一种喹诺酮或萘啶酮类抗生素或其活性化学衍生物与溴己新-HCl 的联合使用，用于治疗人和动物的细菌感染，以及制备上述组合物的工艺。
• Process for the sterilisation of a powder substance
  申请人：I.C.I. International Chemical Industry Spa

  公开号：EP1314439A1

  公开（公告）日：2003-05-28

  A process for the sterilisation of a powder substance is described; in particular, the invention regards the process for the sterilisation of pharmaceutical active principles in powder, including the use of a lyostat in the presence of Hydrogen Peroxide. The invention process makes it possible to sterilise the active principles mentioned without obtaining toxic substances or a change in colour, and without bringing about a decrease in the stability or in the assay of the active principles.

  本发明描述了一种粉末物质的灭菌工艺；特别是粉末中药物活性成分的灭菌工艺，包括在过氧化氢存在下使用溶菌剂。本发明的工艺使上述活性成分的灭菌成为可能，同时不会产生有毒物质或颜色变化，也不会降低活性成分的稳定性或检测能力。
• STABILISED PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THEIR PREPARATION COMPRISING AN ANTIBIOTIC AND AN EXPECTORANT
  申请人：New Pharma Research Sweden AB

  公开号：EP1251874A1

  公开（公告）日：2002-10-30
• US4918108A
  申请人：——

  公开号：US4918108A

  公开（公告）日：1990-04-17
• [EN] STABILISED PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THEIR PREPARATION COMPRISING AN ANTIBIOTIC AND AN EXPECTORANT<br/>[FR] COMPOSITIONS PHARMACEUTIQUES STABILISEES COMPRENANT UN ANTIBIOTIQUE ET UN EXPECTORANT, ET LEUR PROCEDE DE PREPARATION
  申请人：NEW PHARMA RES SWEDEN AB

  公开号：WO2001056610A1

  公开（公告）日：2001-08-09

  Compositions for the prophylactic or therapeutic treatment of bacterial diseases in humans and animals, comprising as essential active ingredients a quinolone- or naphtyridone-type antibiotic or an active chemical derivative thereof and an expectorant, glacial acetic acid, water and a stabilizing agent. The compositions are stable upon storage over a broad range of temperature. The invention concerns also the combined use of a quinolone- or naphtyridone-type antibiotic or an active chemical derivative thereof and an expectorant for the treatment of bacterial infections in humans and animals, and a process for the preparation of the aforementioned compositions.